Literature DB >> 475762

C1 inhibitor-dependent dissociation of human complement component C1 bound to immune complexes.

R B Sim, G J Arlaud, M G Colomb.   

Abstract

The interaction of C1 inhibitor with complement component C1 bound to immune complexes was examined by using 125I-labelled C1 subcomponents. The inhibitor binds rapidly to subcomponent C1s, and more slowly to subcomponent C1r. Formation of the C1r-C1 inhibitor complex causes rapid dissociation of subcomponents C1r and C1s from the antibody-antigen-component C1 aggregate. The rate and extent of this release are proportional to C1 Inhibitor concentration and are also dependent on ionic strength. Results obtained with purified C1 Inhibitor, plasma or serum as source of C1 Inhibitor are all closely comparable. Only slight dissociation of subcomponent C1q is observed under the same range of conditions. The implications of the release phenomenon are discussed in relation to the structure of component C1 and the possibility of differential turnover of C1 subcomponents.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 475762      PMCID: PMC1186649          DOI: 10.1042/bj1790449a

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  35 in total

1.  STUDIES ON HUMAN C'1-ESTERASE. III. EFFECT OF RABBIT ANTI-C'1-ESTERASE ON ENZYMATIC AND COMPLEMENT ACTIVITIES.

Authors:  A L HAINES; I H LEPOW
Journal:  J Immunol       Date:  1964-03       Impact factor: 5.422

2.  Assay and properties of serum inhibitor of C'l-esterase.

Authors:  L R LEVY; I H LEPOW
Journal:  Proc Soc Exp Biol Med       Date:  1959 Aug-Sep

Review 3.  The eleventh Hopkins Memorial Lecture: The biochemistry of complement.

Authors:  R R Porter
Journal:  Biochem Soc Trans       Date:  1977       Impact factor: 5.407

4.  Inhibition of the reconstitution of the haemolytic activity of the first component of human complement by a pepsin-derived fragment of subcomponent C1q.

Authors:  K B Reid; R B Sim; A P Faiers
Journal:  Biochem J       Date:  1977-02-01       Impact factor: 3.857

5.  Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma.

Authors:  R B Sim; A Reboul; G J Arlaud; C L Villiers; M G Colomb
Journal:  FEBS Lett       Date:  1979-01-01       Impact factor: 4.124

6.  Interaction of C1-inhibitor with the C1r and C1s subcomponents in human C1.

Authors:  G J Arlaud; A Reboul; R B Sim; M G Colomb
Journal:  Biochim Biophys Acta       Date:  1979-01-25

7.  The subunit composition and sedimentation properties of human C1.

Authors:  R J Ziccardi; N R Cooper
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

8.  Activation of the first component of human complement (C1) by antibody-antigen aggregates.

Authors:  A W Dodds; R B Sim; R R Porter; M A Kerr
Journal:  Biochem J       Date:  1978-11-01       Impact factor: 3.857

9.  C1 subcomponents in acute pneumococcal otitis media in children.

Authors:  U Johnson; C Kamme; A B Laurell; N I Nilsson
Journal:  Acta Pathol Microbiol Scand C       Date:  1977-02

10.  Lysis of C1Q-coated chicken erythrocytes by human lymphoblastoid cell lines.

Authors:  B Ghebrehiwet; H J Müller-Eberhard
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

View more
  31 in total

1.  Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injury.

Authors:  Valeria Ramaglia; Ruud Wolterman; Maryla de Kok; Miriam Ann Vigar; Ineke Wagenaar-Bos; Rosalind Helen Mary King; Brian Paul Morgan; Frank Baas
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

Review 2.  Biological activities of C1 inhibitor.

Authors:  Alvin E Davis; Pedro Mejia; Fengxin Lu
Journal:  Mol Immunol       Date:  2008-07-31       Impact factor: 4.407

Review 3.  Viral-derived complement inhibitors: current status and potential role in immunomodulation.

Authors:  Hadi Abou-El-Hassan; Hassan Zaraket
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-26

4.  Domain structure and associated functions of subcomponents C1r and C1s of the first component of human complement.

Authors:  C L Villiers; G J Arlaud; M G Colomb
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

5.  Molecular modelling of human complement subcomponent C1q and its complex with C1r2C1s2 derived from neutron-scattering curves and hydrodynamic properties.

Authors:  S J Perkins
Journal:  Biochem J       Date:  1985-05-15       Impact factor: 3.857

6.  The crystal structure of the zymogen catalytic domain of complement protease C1r reveals that a disruptive mechanical stress is required to trigger activation of the C1 complex.

Authors:  Monika Budayova-Spano; Monique Lacroix; Nicole M Thielens; Gérard J Arlaud; Juan Carlos Fontecilla-Camps; Christine Gaboriaud
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

7.  Complement C4 monitoring in the follow-up of chronic hepatitis C treatment.

Authors:  C Dumestre-Perard; D Ponard; C Drouet; V Leroy; J-P Zarski; N Dutertre; M G Colomb
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

8.  Characterization of C1q-binding material released from the membranes of Raji and U937 cells by limited proteolysis with trypsin.

Authors:  A Erdei; K B Reid
Journal:  Biochem J       Date:  1988-10-15       Impact factor: 3.857

9.  Identification of the Raji cell membrane-derived C1q inhibitor as a receptor for human C1q. Purification and immunochemical characterization.

Authors:  B Ghebrehiwet; L Silvestri; C McDevitt
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

10.  C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.

Authors:  G Doekes; L A van Es; M R Daha
Journal:  Immunology       Date:  1983-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.